Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: genocea.com
SVB Leerink reiterated coverage of Genocea Biosciences with a rating of Outperform and set a new price target of $6.00 from $5.00 previously
Needham reiterated coverage of Genocea Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the third quarter ended September 30, 2021. "We continue to make significant progress. Most notably, we are very excited about our TiTAN™ clinical trial for GEN-011, our neoantigen-targeted peripheral T cell therapy (NPT) candidate, from which we expect to have initial data from a small subset of patient
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8729366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will be available on the Genocea we
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 6789021. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will be ava
15-12B - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
25 - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company's ongoing operations and terminate the Company's remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the Nasdaq Capital Market in connection with the wind down of its operations. The Company plans to file a Form 25 with the Securities and Exchange Commission on or about June 2
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company, merger or reverse merger. As we pursue strategic alternatives, the Company has put into place a restructuring plan which includes an approximate 65% reduction in workforce in the second q
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANETTM manufacturing process is highly reliable and continues to improve; patients next to be dosed to receive GEN-011 with substantially boosted yields, neoantigen specificity and potency Investor webcast at 4:30 pm ET today to further discuss data CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation n
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss previously announced AACR presentations, including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripheral T cell therapy product candidate GEN-011, and results demonstrating successful pro
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A replay of the webcast will be archived for 90 days following the presentation. About Genocea Biosciences, Inc.Genocea'
Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy candidate. GEN-011 is comprised only of CD8+ and CD4+ T cells, extracted from the patient's peripheral blood and specific for ATLAS-prioritized neoantigens. Pat
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably generates abundant, high-quality neoantigen-specific T cellsPreclinical data indicate that Inhibigens™ accelerate tumor growth in animal models of pancreatic cancer and melanoma CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present clinical, preclinical, and manufacturing data at next month's American Association for Cancer Research (AACR) Annual Meeting 2
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that John Lunger, Chief Patient Supply Officer at Adaptimmune Therapeutics plc ("Adaptimmune"), has joined its board of directors. "It is my pleasure to welcome John to our board of directors," said Chip Clark, Genocea's President and Chief Executive Officer. "Scaling our technical operations to ensure the reliable delivery of cost-effective cell therapies is a strategic priority. I am confident John's experiences and expertise will prove invaluable to us on this and many other matters." Mr. Lu
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET. A live webcast of the presentation will be available in the "Events and Presentations" tab of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A replay of the webcast will be archived for 90 days following the presentation. About Genocea Bioscience
SC 13D/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. Genocea Biosciences, Inc. (NASDAQ:GNCA), which announced on May 24 plans to wind down of operations, continued to see weakness, ending the week down over 66%. The company is awaiting delisting of its stock from Nasdaq. Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) shares also came under intense selling pressure after it announced the Food and Drug Administration's decision to issue a refusal-to-file letter for its Arginase 1 deficiency treatment candidate. The week witnessed some activity on the M&A front. GlaxoSmithKline plc (NYSE:GSK) confirmed the
Gainers NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares gained 47.5% to settle at $0.8436 on Thursday. Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) recently determined that the evaluation of NRx Pharmaceuticals’ Zyesami (aviptadil) should cease due to futility. Repare Therapeutics Inc. (NASDAQ:RPTX) surged 44.8% to close at $12.67 on Thursday after the company announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib. Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential milestones. Talk
On Tuesday, 36 companies achieved new lows for the year. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Clearwater Analytics Hldg (NYSE:CWAN). The smallest company in terms of market cap to set a new 52-week low was Genocea Biosciences (NASDAQ:GNCA). Outlook Therapeutics (NASDAQ:OTLK)'s stock fell the most, as it traded down 37.33% to reach a new 52-week low. Burning Rock Biotech (NASDAQ:BNR)'s stock showed potential to rebound, rebounding up 0.69% after reaching a new 52-week low. On Tuesday, the following stocks set new 52-week lows: Clearwater Analytics Hldg (NYSE:CWAN) stock broke to a new 52-week low
Gainers TherapeuticsMD (NASDAQ:TXMD) stock rose 340.6% to $9.43 during Tuesday's pre-market session. The company's market cap stands at $81.7 million. Endo International (NASDAQ:ENDP) stock increased by 12.76% to $0.53. The market value of their outstanding shares is at $124.6 million. Atreca (NASDAQ:BCEL) shares moved upwards by 10.71% to $1.86. The market value of their outstanding shares is at $71.7 million. Eledon Pharma (NASDAQ:ELDN) shares moved upwards by 10.64% to $3.95. The market value of their outstanding shares is at $54.3 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 8.99% to $0.47. The company's market cap stands at $12.5 million. First Wave BioPharma (NA
Gainers Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug. Oncternal Therapeutics, Inc. (NASDAQ:ONCT) jumped 88.1% to settle at $1.54. Oncternal Therapeutics presented updated interim data for zilovertamab in combination with ibrutinib at ASCO 2022. SIGA Technologies, Inc. (NASDAQ:SIGA) climbed 41.9% to close at $13.68. European Union has agreed to buy Bavarian Nordic's Imvanex, Tecoviriat from Siga in the US. Allarity Therapeutics, Inc. (NASDAQ:ALLR) rose 39.3% to close at $2.87 after Ladenburg Thalmann initiated coverage on t
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period. Among notable developments, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced that it is shuttering operations amid a cash crunch. The company also plans to voluntarily delist its shares from Nasdaq by June 2. Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) suffered a setback after its viral skin infection treatment candidate was rejected by the Food and Drug Administration on its third try. Catalyst Biosciences, Inc. (NASDAQ:CBIO) shares skyrocketed after the company a
Gainers Creatd, Inc. (NASDAQ:CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. Apyx Medical Corporation (NASDAQ:APYX) rose 51.9% to settle at $5.62 after the company received the FDA 510(k) clearance for use of renuvion cosmetic technology in dermal resurfacing procedures. Planet Green Holdings Corp. (NYSE:PLAG) gained 51.2% to close at $0.70. Planet Green recently reported a $4 million offering. SciSparc Ltd. (NASDAQ:SPRC) shares surged 41.1% to close at $3.33. SciSparc reported Ethics Committee approval to conduct a Phase IIb trial in Tourette Syndrome. Guardion Health Scienc
Gainers Apyx Medical (NASDAQ:APYX) shares increased by 44.6% to $5.35 during Thursday's regular session. Trading volume for Apyx Medical's stock is 19.6 million as of 13:30 EST. This is 12620.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $184.3 million. Talkspace (NASDAQ:TALK) shares increased by 36.79% to $1.45. As of 13:30 EST, Talkspace's stock is trading at a volume of 6.0 million, which is 926.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $224.9 million. OpGen (NASDAQ:OPGN) shares rose 25.82% to $0.47. As of 13:30 EST, this security is trading at a volume
Gainers Healthcare Triangle, Inc. (NASDAQ:HCTI) shares gained 46.6% to $0.9824. Healthcare Triangle recently posted a Q1 loss of $0.06 per share. Planet Green Holdings Corp. (NYSE:PLAG) rose 44.6% to $0.6698. Planet Green recently reported a $4 million offering. SciSparc Ltd. (NASDAQ:SPRC) shares jumped 41.5% to $3.3389. SciSparc reported Ethics Committee approval to conduct a Phase IIb trial in Tourette Syndrome. Guardion Health Sciences, Inc. (NASDAQ:GHSI) gained 38.3% to $0.2060. Guardion Health Sciences said its new Viactiv Omega Boost Gel Bites is now available for purchase on Amazon. Apyx Medical Corporation (NASDAQ:APYX) gained 37.3% to $5.08 after the company received the FDA
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 71.6% to $1.09 during Thursday's pre-market session. The market value of their outstanding shares is at $30.5 million. Reshape Lifesciences (NASDAQ:RSLS) stock rose 15.49% to $0.82. The company's market cap stands at $2.8 million. As per the news, the Q1 earnings report came out 3 days ago. Monopar Therapeutics (NASDAQ:MNPR) shares moved upwards by 14.81% to $2.48. The company's market cap stands at $31.2 million. Liquidia (NASDAQ:LQDA) shares moved upwards by 9.04% to $3.98. The market value of their outstanding shares is at $256.0 million. Evelo Biosciences (NASDAQ:EVLO) shares increased by 8.88% to $1.96. The company's mark